373 related articles for article (PubMed ID: 4742736)
1. Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors.
Fambrough DM; Drachman DB; Satyamurti S
Science; 1973 Oct; 182(4109):293-5. PubMed ID: 4742736
[TBL] [Abstract][Full Text] [Related]
2. Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors.
Almon RR; Andrew CG; Appel SH
Science; 1974 Oct; 186(4158):55-7. PubMed ID: 4421998
[TBL] [Abstract][Full Text] [Related]
3. A non-immunogenic myasthenia gravis model and its application in a study of transsynaptic regulation at the neuromuscular junction.
Molenaar PC; Oen BS; Plomp JJ; Van Kempen GT; Jennekens FG; Hesselmans LF
Eur J Pharmacol; 1991 Apr; 196(1):93-101. PubMed ID: 1874282
[TBL] [Abstract][Full Text] [Related]
4. Acetylcholine receptors and end-plate electrophysiology in myasthenia gravis.
Ito Y; Miledi R; Vincent A; Newsom-Davis J
Brain; 1978 Jun; 101(2):345-68. PubMed ID: 667602
[No Abstract] [Full Text] [Related]
5. Myasthenia gravis as a receptor disorder.
Drachman DB; Kao I; Pestronk A; Toyka KV
Ann N Y Acad Sci; 1976; 274():226-34. PubMed ID: 786108
[No Abstract] [Full Text] [Related]
6. Congenital myasthenia: end-plate acetylcholine receptors and electrophysiology in five cases.
Vincent A; Cull-Candy SG; Newsom-Davis J; Trautmann A; Molenaar PC; Polak RL
Muscle Nerve; 1981; 4(4):306-18. PubMed ID: 7254233
[TBL] [Abstract][Full Text] [Related]
7. Measurement of junctional acetylcholine receptors in myasthenia gravis: clinical correlates.
Pestronk A; Drachman DB; Self SG
Muscle Nerve; 1985; 8(3):245-51. PubMed ID: 4058469
[TBL] [Abstract][Full Text] [Related]
8. Effect of myasthenic immunoglobulin on acetylcholine receptors of intact mammalian neuromuscular junctions.
Stanley EF; Drachman DB
Science; 1978 Jun; 200(4347):1285-7. PubMed ID: 663610
[TBL] [Abstract][Full Text] [Related]
9. Experimental autoimmune myasthenia gravis: can pretreatment with 125I-labeled receptor prevent functional damage at the neuromuscular junction?
Sterz RK; Biro G; Rajki K; Filipp G; Peper K
J Immunol; 1985 Feb; 134(2):841-6. PubMed ID: 2578165
[TBL] [Abstract][Full Text] [Related]
10. Interaction of myasthenic serum globulin with the acetylcholine receptor.
Almon RR; Appel SH
Biochim Biophys Acta; 1975 May; 393(1):66-77. PubMed ID: 1138925
[TBL] [Abstract][Full Text] [Related]
11. Acetylcholine receptor in myasthenia gravis: increased affinity for alpha-bungarotoxin.
Elias SB; Appel SH
Ann Neurol; 1978 Sep; 4(3):250-2. PubMed ID: 718136
[TBL] [Abstract][Full Text] [Related]
12. The kinetics of transmitter release in myasthenia gravis. I. An electrophysiological analysis of the storage of transmitter.
Bergmans J; Rosselle N; Verheyen G; Schellens L
Electromyogr Clin Neurophysiol; 1972; 12(5):443-88. PubMed ID: 4350884
[No Abstract] [Full Text] [Related]
13. Localization of acetylcholine receptor by 125I-labeled alpha-bungarotoxin binding at mouse motor endplates.
Fertuck HC; Salpeter MM
Proc Natl Acad Sci U S A; 1974 Apr; 71(4):1376-8. PubMed ID: 4524643
[TBL] [Abstract][Full Text] [Related]
14. Role of Munc18-1 in synaptic plasticity at the myasthenic neuromuscular junction.
Sons MS; Verhage M; Plomp JJ
Ann N Y Acad Sci; 2003 Sep; 998():404-6. PubMed ID: 14592907
[No Abstract] [Full Text] [Related]
15. Pathological mechanisms in experimental autoimmune myasthenia gravis. I. Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental automimmune myasthenia gravis.
Lindstrom JM; Einarson BL; Lennon VA; Seybold ME
J Exp Med; 1976 Sep; 144(3):726-38. PubMed ID: 182896
[TBL] [Abstract][Full Text] [Related]
16. The acetylcholine receptor in normal and pathologic states. Immunoperoxidase visualization of alpha-bungarotoxin binding at a light and electron-microscopic level.
Bender AN; Ringel SP; Engel WK
Neurology; 1976 May; 26(5):477-83. PubMed ID: 177905
[TBL] [Abstract][Full Text] [Related]
17. An electrophysiological and morphological study of the neuromuscular junction in patients with myasthenia gravis.
Albuquerque EX; Rash JE; Mayer RF; Satterfield JR
Exp Neurol; 1976 Jun; 51(3):536-63. PubMed ID: 179836
[No Abstract] [Full Text] [Related]
18. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
[TBL] [Abstract][Full Text] [Related]
19. [Neurophysiological testing in myasthenia syndromes].
Kostera-Pruszczyk A; Rowińska-Marcińska K; Emeryk-Szajewska B
Neurol Neurochir Pol; 2003; 37(1):161-72. PubMed ID: 12910838
[TBL] [Abstract][Full Text] [Related]
20. Utrophin abundance is reduced at neuromuscular junctions of patients with both inherited and acquired acetylcholine receptor deficiencies.
Slater CR; Young C; Wood SJ; Bewick GS; Anderson LV; Baxter P; Fawcett PR; Roberts M; Jacobson L; Kuks J; Vincent A; Newsom-Davis J
Brain; 1997 Sep; 120 ( Pt 9)():1513-31. PubMed ID: 9313636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
